Adenoviridae infectious disease

Summary

Adenoviridae infectious disease (MONDO:0043479) is a disease and 23 clinical trials. Top therapeutic interventions include brincidofovir, cidofovir anhydrous, and ganciclovir. A subtype of primary viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 23

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adenoviridae infectious disease
Mondo ID	MONDO:0043479
MeSH	D000257
NCIT	C115149
SNOMED CT	25225006
UMLS	C0001486
MedGen	1754
Is cancer (heuristic)	no

Also known as: Adenoviridae caused disease or disorder · Adenoviridae disease or disorder · Adenoviridae infection · Adenoviridae infectious disease · adenoviridae infectious disease · adenovirus infection · adenovirus infections · disease due to adenovirus · infection, Adenoviridae · infection, adenovirus · infections, Adenoviridae · infections, adenovirus

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › adenoviridae infectious disease

Related subtypes (31): plantar wart, monkeypox, smallpox, rubella, human papilloma virus infection, Rotavirus infection, Arenaviridae infectious disease, Astroviridae infectious disease, Caliciviridae infectious disease, cowpox, Flaviviridae infectious disease, Hepadnaviridae infectious disease, Herpesviridae infectious disease, influenza, Mononegavirales infectious disease, Nidovirales infectious disease, phlebotomus fever, Picornaviridae infectious disease, polyomavirus infectious disease, Togaviridae infectious disease, viral encephalitis, viral hepatitis, viral pneumonia, viral exanthem, deltaretrovirus infections, Bunyaviridae infectious disease, viral sexually transmitted disease, lentivirus infection, viral myocarditis, viral pericarditis, aleutian mink disease, human

Subtypes (2): epidemic keratoconjunctivitis, adenovirus renal infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Brincidofovir	Phase 3
Posoleucel	Phase 3

Clinical trials & evidence

Clinical trials

Clinical trials: 23.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	7
PHASE1	6
PHASE2/PHASE3	3
PHASE3	3
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07387367	PHASE3	RECRUITING	A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT00302640	PHASE2/PHASE3	COMPLETED	Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children
NCT02087306	PHASE3	COMPLETED	Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
NCT04693637	PHASE2/PHASE3	COMPLETED	Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
NCT05179057	PHASE3	TERMINATED	Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
NCT05305040	PHASE2/PHASE3	TERMINATED	Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
NCT02007356	PHASE2	RECRUITING	A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
NCT03475212	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
NCT04706923	PHASE2	RECRUITING	A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04722029	PHASE1/PHASE2	RECRUITING	Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
NCT00711035	PHASE1/PHASE2	COMPLETED	Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
NCT01325636	PHASE1/PHASE2	COMPLETED	Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
NCT02702427	PHASE1/PHASE2	WITHDRAWN	Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation
NCT02851576	PHASE1/PHASE2	COMPLETED	Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV)
NCT03159364	PHASE1/PHASE2	UNKNOWN	Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
NCT05101213	PHASE1	RECRUITING	Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
NCT00590083	PHASE1	COMPLETED	Administration of Virus-Specific Cytotoxic T-Lymphocytes
NCT00880789	PHASE1	COMPLETED	Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
NCT01070797	PHASE1	COMPLETED	Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
NCT01923766	PHASE1	COMPLETED	Cytotoxic T Cells to Prevent Virus Infections
NCT02276820	PHASE1	WITHDRAWN	Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
NCT07104591	Not specified	AVAILABLE	TETRAVI Expanded Access Program
NCT01349452	Not specified	COMPLETED	Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BRINCIDOFOVIR	4	2
CIDOFOVIR ANHYDROUS	4	2
GANCICLOVIR	4	1
NITAZOXANIDE	4	1
POSOLEUCEL	3	3